Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068523 · ClinicalTrials.gov registry record · NA
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
A NA study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00068523 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00068523, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells. Ultraviolet-B light therapy given before and after allogeneic stem cell transplantation may help prevent this from happening. PURPOSE: Clinical trial to study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.
Interventions
- DRUG cyclophosphamide
- DRUG methylprednisolone
- DRUG fludarabine phosphate
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2003-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068523
The ClinicalTrials.gov registry entry for NCT00068523 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00068523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068523 about?
NCT00068523 is a clinical study titled "Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells. Ultraviolet-B light therapy given before and after allogeneic stem cell transplantation may ...
What is the current status of trial NCT00068523?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2003-06.
What interventions are being tested in trial NCT00068523?
The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), fludarabine phosphate (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00068523?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.